[go: up one dir, main page]

Glenner, 1990 - Google Patents

Alzheimer's Disease: Enter Protein Chemistry

Glenner, 1990

Document ID
7606613905536807559
Author
Glenner G
Publication year
Publication venue
Biomedical advances in aging

External Links

Snippet

With the evidence that autopsies of demented individuals over the age of 65 demonstrate a predominance of lesions normally associated with Alzheimer's disease, ie, neurofibrillary tangles and “senile”(neuritic plaques)(Tomlinson et al., 1968, 1970), the significance of …
Continue reading at link.springer.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Selkoe Molecular pathology of amyloidogenic proteins and the role of vascular amyloidosis in Alzheimer's disease
Tagliavini et al. Amyloid fibrils in Gerstmann-Sträussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele
Selkoe The deposition of amyloid proteins in the aging mammalian brain: implications for Alzheimer's disease
Van Duinen et al. Hereditary cerebral hemorrhage with amyloidosis in patients of Dutch origin is related to Alzheimer disease.
Ghetti et al. Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP.
Podlisny et al. Homology of the amyloid beta protein precursor in monkey and human supports a primate model for beta amyloidosis in Alzheimer's disease
Tabaton et al. Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid
EP0970203B1 (en) Agents for pre-symptomatic detection and therapeutic targeting of alzheimer's disease in humans
Abraham et al. α1-Antichymotrypsin is associated solely with amyloid deposits containing the β-protein. Amyloid and cell localization of α1-antichymotrypsin
Teplow Structural and kinetic features of amyloid β-protein fibrillogenesis
Mullan et al. Genetics and molecular advances in Alzheimer's disease
Abraham et al. α1-Antichymotrypsin is present together with the β-protein in monkey brain amyloid deposits
Adler et al. Increased gene expression of Alzheimer disease beta-amyloid precursor protein in senescent cultured fibroblasts.
JP4454230B2 (en) β-secretase substrate and use thereof
Kaplan et al. [5] Microextraction and purification techniques applicable to chemical characterization of amyloid proteins in minute amounts of tissue
KR20070073743A (en) Antibodies and Their Use
EP2224000A1 (en) Antibody and use thereof
Giaccone et al. beta PP and Tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease
Abraham et al. Alzheimer's disease: recent advances in understanding the brain amyloid deposits
Chikugo et al. Optimization of the Linker Length in the Dimer Model of E22P-Aβ40 Tethered at Position 38
Glenner Alzheimer’s Disease: Enter Protein Chemistry
Joachim et al. Minireview: amyloid protein in Alzheimer's disease
GLENNER Alzheimer's Disease Enter Protein Chemistry
Löffler et al. Accumulation of a 50 kDa N-terminal fragment of β-APP695 in Alzheimer's disease hippocampus and neocortex
JP2008291025A (en) Human amylospheroid-like aggregates